|
Gene: ST14 |
Gene summary for ST14 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ST14 | Gene ID | 6768 |
Gene name | ST14 transmembrane serine protease matriptase | |
Gene Alias | ARCI11 | |
Cytomap | 11q24.3 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q9Y5Y6 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6768 | ST14 | HTA11_2487_2000001011 | Human | Colorectum | SER | 5.43e-14 | 9.40e-01 | -0.1808 |
6768 | ST14 | HTA11_1938_2000001011 | Human | Colorectum | AD | 6.16e-15 | 1.02e+00 | -0.0811 |
6768 | ST14 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.74e-46 | 1.25e+00 | -0.1954 |
6768 | ST14 | HTA11_411_2000001011 | Human | Colorectum | SER | 2.62e-14 | 1.93e+00 | -0.2602 |
6768 | ST14 | HTA11_2112_2000001011 | Human | Colorectum | SER | 1.43e-16 | 1.49e+00 | -0.2196 |
6768 | ST14 | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.57e-12 | 9.54e-01 | -0.1207 |
6768 | ST14 | HTA11_83_2000001011 | Human | Colorectum | SER | 1.52e-13 | 9.74e-01 | -0.1526 |
6768 | ST14 | HTA11_696_2000001011 | Human | Colorectum | AD | 4.24e-39 | 1.25e+00 | -0.1464 |
6768 | ST14 | HTA11_866_2000001011 | Human | Colorectum | AD | 2.90e-19 | 7.88e-01 | -0.1001 |
6768 | ST14 | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.84e-22 | 1.19e+00 | -0.059 |
6768 | ST14 | HTA11_2992_2000001011 | Human | Colorectum | SER | 3.83e-04 | 7.27e-01 | -0.1706 |
6768 | ST14 | HTA11_5212_2000001011 | Human | Colorectum | AD | 4.70e-09 | 9.95e-01 | -0.2061 |
6768 | ST14 | HTA11_5216_2000001011 | Human | Colorectum | SER | 3.42e-08 | 9.10e-01 | -0.1462 |
6768 | ST14 | HTA11_546_2000001011 | Human | Colorectum | AD | 8.41e-16 | 1.10e+00 | -0.0842 |
6768 | ST14 | HTA11_866_3004761011 | Human | Colorectum | AD | 1.74e-25 | 1.10e+00 | 0.096 |
6768 | ST14 | HTA11_8622_2000001021 | Human | Colorectum | SER | 5.15e-05 | 7.56e-01 | 0.0528 |
6768 | ST14 | HTA11_7663_2000001011 | Human | Colorectum | SER | 6.11e-14 | 1.18e+00 | 0.0131 |
6768 | ST14 | HTA11_10623_2000001011 | Human | Colorectum | AD | 9.32e-14 | 1.01e+00 | -0.0177 |
6768 | ST14 | HTA11_6801_2000001011 | Human | Colorectum | SER | 4.73e-05 | 8.03e-01 | 0.0171 |
6768 | ST14 | HTA11_10711_2000001011 | Human | Colorectum | AD | 3.05e-12 | 7.75e-01 | 0.0338 |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:006071114 | Skin | SCCIS | labyrinthine layer development | 8/919 | 44/18723 | 1.20e-03 | 1.42e-02 | 8 |
GO:0001701110 | Skin | SCCIS | in utero embryonic development | 32/919 | 367/18723 | 1.23e-03 | 1.45e-02 | 32 |
GO:0001892110 | Skin | SCCIS | embryonic placenta development | 11/919 | 82/18723 | 2.16e-03 | 2.18e-02 | 11 |
GO:000183815 | Skin | SCCIS | embryonic epithelial tube formation | 14/919 | 121/18723 | 2.45e-03 | 2.40e-02 | 14 |
GO:003514817 | Skin | SCCIS | tube formation | 16/919 | 148/18723 | 2.52e-03 | 2.44e-02 | 16 |
GO:002191513 | Skin | SCCIS | neural tube development | 16/919 | 152/18723 | 3.30e-03 | 2.97e-02 | 16 |
GO:006071316 | Skin | SCCIS | labyrinthine layer morphogenesis | 5/919 | 22/18723 | 3.69e-03 | 3.22e-02 | 5 |
GO:000338212 | Skin | SCCIS | epithelial cell morphogenesis | 6/919 | 33/18723 | 4.88e-03 | 3.99e-02 | 6 |
GO:007217513 | Skin | SCCIS | epithelial tube formation | 14/919 | 132/18723 | 5.40e-03 | 4.29e-02 | 14 |
GO:000170124 | Skin | cSCC | in utero embryonic development | 150/4864 | 367/18723 | 2.47e-10 | 1.04e-08 | 150 |
GO:004358823 | Skin | cSCC | skin development | 111/4864 | 263/18723 | 6.35e-09 | 2.10e-07 | 111 |
GO:000854425 | Skin | cSCC | epidermis development | 131/4864 | 324/18723 | 7.38e-09 | 2.39e-07 | 131 |
GO:003021622 | Skin | cSCC | keratinocyte differentiation | 59/4864 | 139/18723 | 1.70e-05 | 2.07e-04 | 59 |
GO:000189223 | Skin | cSCC | embryonic placenta development | 39/4864 | 82/18723 | 2.08e-05 | 2.43e-04 | 39 |
GO:006145825 | Skin | cSCC | reproductive system development | 149/4864 | 427/18723 | 2.30e-05 | 2.65e-04 | 149 |
GO:004860824 | Skin | cSCC | reproductive structure development | 148/4864 | 424/18723 | 2.40e-05 | 2.74e-04 | 148 |
GO:000189024 | Skin | cSCC | placenta development | 60/4864 | 144/18723 | 2.84e-05 | 3.17e-04 | 60 |
GO:000206426 | Skin | cSCC | epithelial cell development | 84/4864 | 220/18723 | 4.33e-05 | 4.56e-04 | 84 |
GO:000991324 | Skin | cSCC | epidermal cell differentiation | 78/4864 | 202/18723 | 5.12e-05 | 5.28e-04 | 78 |
GO:006066916 | Skin | cSCC | embryonic placenta morphogenesis | 16/4864 | 26/18723 | 1.39e-04 | 1.26e-03 | 16 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ST14 | SNV | Missense_Mutation | c.2086N>T | p.Arg696Cys | p.R696C | Q9Y5Y6 | protein_coding | deleterious(0) | probably_damaging(0.973) | TCGA-BH-A0B8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | |
ST14 | SNV | Missense_Mutation | c.2174N>T | p.Ser725Phe | p.S725F | Q9Y5Y6 | protein_coding | deleterious(0.01) | possibly_damaging(0.575) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
ST14 | SNV | Missense_Mutation | rs749681872 | c.113N>C | p.Phe38Ser | p.F38S | Q9Y5Y6 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-E2-A156-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
ST14 | SNV | Missense_Mutation | c.1560N>C | p.Glu520Asp | p.E520D | Q9Y5Y6 | protein_coding | deleterious(0.02) | probably_damaging(1) | TCGA-E2-A1LI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
ST14 | SNV | Missense_Mutation | novel | c.1622N>T | p.Ser541Ile | p.S541I | Q9Y5Y6 | protein_coding | deleterious(0.04) | possibly_damaging(0.632) | TCGA-E9-A2JS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamide | PD |
ST14 | SNV | Missense_Mutation | c.923N>G | p.Ser308Cys | p.S308C | Q9Y5Y6 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-GM-A2DH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR | |
ST14 | SNV | Missense_Mutation | novel | c.1053N>A | p.Phe351Leu | p.F351L | Q9Y5Y6 | protein_coding | tolerated(0.08) | benign(0.02) | TCGA-C5-A2LZ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD |
ST14 | SNV | Missense_Mutation | novel | c.2360G>A | p.Arg787His | p.R787H | Q9Y5Y6 | protein_coding | deleterious(0.03) | possibly_damaging(0.572) | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ST14 | SNV | Missense_Mutation | c.1631N>A | p.Cys544Tyr | p.C544Y | Q9Y5Y6 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
ST14 | SNV | Missense_Mutation | novel | c.1193C>T | p.Pro398Leu | p.P398L | Q9Y5Y6 | protein_coding | tolerated(0.74) | benign(0.029) | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6768 | ST14 | ENZYME, DRUGGABLE GENOME, PROTEASE | US8569313, Inhibitor 14 | |||
6768 | ST14 | ENZYME, DRUGGABLE GENOME, PROTEASE | inhibitor | 252166696 | ||
6768 | ST14 | ENZYME, DRUGGABLE GENOME, PROTEASE | US8569313, Inhibitor 19 | |||
6768 | ST14 | ENZYME, DRUGGABLE GENOME, PROTEASE | US8569313, Inhibitor 18 | |||
6768 | ST14 | ENZYME, DRUGGABLE GENOME, PROTEASE | SURAMIN | SURAMIN | 15590895 | |
6768 | ST14 | ENZYME, DRUGGABLE GENOME, PROTEASE | inhibitor | 405067326 | ||
6768 | ST14 | ENZYME, DRUGGABLE GENOME, PROTEASE | PROTEASE INHIBITOR | 10373425 | ||
6768 | ST14 | ENZYME, DRUGGABLE GENOME, PROTEASE | inhibitor | 252166825 | ||
6768 | ST14 | ENZYME, DRUGGABLE GENOME, PROTEASE | US8569313, Inhibitor 15 | |||
6768 | ST14 | ENZYME, DRUGGABLE GENOME, PROTEASE | inhibitor | 252166691 |
Page: 1 |